Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6) given in the specification and below, are new. Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6): (a) AsnTyrTrpLeuGly (1)； (b) AspIleTyrPro(Gly) 3TyrThrAsnTyrAsnGluLysPheLysGly (2)； (c) AspIleTyrPro(Gly) 2SerTyrThrAsnTyrAsnGluLysPheLysGly (3)； (d) TyrAspAlaAlaGlyProTrpPheAlaTyr (4)； (e) TyrAspAlaAlaGlyProGlyPheAlaTyr (5)； or (f) TyrAspAsnHisTyrPheAspTyr (6). Independent claims are also included for: (1) construct (B) consisting of (A) fused, chemically coupled or non-covalently associated with additional sequences and/or structures； (2) isolated nucleic acid (NA) containing sequences that encode at least one (A) or (B)； (3) expression cassette or vector (X) comprising NA and functionally linked promoter； (4) virus or host cell that contains at least one (X)； (5) organism that contains at least one host cell of (4)； (6) method for preparing (A)； and (7) kit containing (A) and/or (B). ACTIVITY : Cytostatic. A multibody (104； sequence of about 200 amino acids reproduced) was coupled to a chelating group then loaded with yttrium99. It was injected (dose 100 MicroCi) into the tail vein of a mouse, subcutaneously implanted with ZA-75-1 (Core-1 positive) tumor cells. A second dose was given after 3 weeks and this treatment produced a significant reduction in tumor growth (no figures given). MECHANISM OF ACTION : Neutralization of Core-1 antigen； Vaccine.
